메뉴 건너뛰기




Volumn 137, Issue 10, 2011, Pages 1563-1569

Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS

Author keywords

Acute myeloid leukemia; Cytarabine; Granulocyte colony stimulating factor (G CSF); Homoharringtonine; Myelodysplastic syndromes

Indexed keywords

CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; IDARUBICIN; LACTATE DEHYDROGENASE;

EID: 80054766412     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1020-2     Document Type: Article
Times cited : (21)

References (25)
  • 1
    • 0017153556 scopus 로고
    • Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment
    • Cephalotaxus Research Coordinating Group
    • Cephalotaxus Research Coordinating Group (1976) Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J 2(4):263-272
    • (1976) Chin Med J , vol.2 , Issue.4 , pp. 263-272
  • 4
    • 0023096812 scopus 로고
    • Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy
    • Delacretaz F, Schmidt PM, Piguet D, Bachmann F, Costa J (1987). Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol 87(2):180-186 (Pubitemid 17022456)
    • (1987) American Journal of Clinical Pathology , vol.87 , Issue.2 , pp. 180-186
    • Delacretaz, F.1    Schmidt, P.-M.2    Piguet, D.3
  • 5
    • 62849104641 scopus 로고    scopus 로고
    • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
    • 19230772 10.1016/S1470-2045(09)70003-8 1:CAS:528:DC%2BD1MXisFWjsbc%3D
    • P Fenaux GJ Mufti E Hellstrom-Lindberg, et al. 2009 Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 3 223 232 19230772 10.1016/S1470-2045(09)70003-8 1:CAS:528:DC%2BD1MXisFWjsbc%3D
    • (2009) Lancet Oncol , vol.10 , Issue.3 , pp. 223-232
    • Fenaux, P.1    Mufti, G.J.2    Hellstrom-Lindberg, E.3
  • 8
    • 0003328595 scopus 로고
    • Guidelines for cancer cytogenetics
    • ISCN (International System for Human Cytogenetic Nomenclature) Karger, Basel
    • ISCN (International System for Human Cytogenetic Nomenclature) (1991) Guidelines for cancer cytogenetics. In: Mitelman F (ed) Supplement to an International System for Human Cytogenetic Nomenclature. Karger, Basel, pp 1-53
    • (1991) Supplement to An International System for Human Cytogenetic Nomenclature , pp. 1-53
    • Mitelman, F.1
  • 9
    • 33746105303 scopus 로고    scopus 로고
    • Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia
    • DOI 10.1038/sj.leu.2404287, PII 2404287
    • J Jin DZ Jiang WY Mai, et al. 2006 Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia Leukemia 20 8 1361 1367 16791270 10.1038/sj.leu.2404287 1:CAS:528:DC%2BD28XntVWksro%3D (Pubitemid 44084048)
    • (2006) Leukemia , vol.20 , Issue.8 , pp. 1361-1367
    • Jin, J.1    Jiang, D.-Z.2    Mai, W.-Y.3    Meng, H.-T.4    Qian, W.-B.5    Tong, H.-Y.6    Huang, J.7    Mao, L.-P.8    Tong, Y.9    Wang, L.10    Chen, Z.-M.11    Xu, W.-L.12
  • 10
    • 0024518154 scopus 로고
    • Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia
    • DOI 10.1002/1097-0142(19890301)63:5<813::AID-CNCR2820630502>3.0. CO;2-V
    • HM Kantarjian MJ Keating RS Walters CA Koller KB McCredie EJ Freireich 1989 Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia Cancer 63 5 813 817 2914287 10.1002/1097-0142(19890301)63:5<813::AID-CNCR2820630502>3.0.CO;2-V 1:STN:280:DyaL1M7hvFeksA%3D%3D (Pubitemid 19063182)
    • (1989) Cancer , vol.63 , Issue.5 , pp. 813-817
    • Kantarjian, H.M.1    Keating, M.J.2    Walters, R.S.3    Koller, C.A.4    McCredie, K.B.5    Freireich, E.J.6
  • 11
    • 33646071894 scopus 로고    scopus 로고
    • Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study
    • 16532500 10.1002/cncr.21792 1:CAS:528:DC%2BD28XksFCrsrk%3D
    • H Kantarjian JP Issa CS Rosenfeld, et al. 2006 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 8 1794 1803 16532500 10.1002/cncr.21792 1:CAS:528: DC%2BD28XksFCrsrk%3D
    • (2006) Cancer , vol.106 , Issue.8 , pp. 1794-1803
    • Kantarjian, H.1    Issa, J.P.2    Rosenfeld, C.S.3
  • 12
    • 33644521267 scopus 로고    scopus 로고
    • Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome
    • 16435386 10.1002/cncr.21723
    • H Kantarjian S O'brien J Cortes, et al. 2006 Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome Cancer 106 5 1090 1098 16435386 10.1002/cncr.21723
    • (2006) Cancer , vol.106 , Issue.5 , pp. 1090-1098
    • Kantarjian, H.1    O'Brien, S.2    Cortes, J.3
  • 13
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observation
    • 10.2307/2281868
    • E Kaplan P Meier 1958 Nonparametric estimation from incomplete observation J Am Statist Assoc 53 282 457 481 10.2307/2281868
    • (1958) J Am Statist Assoc , vol.53 , Issue.282 , pp. 457-481
    • Kaplan, E.1    Meier, P.2
  • 14
    • 27244459396 scopus 로고    scopus 로고
    • Aclarubicin and low-dose cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: A multicenter study of 112 Chinese patients
    • DOI 10.1532/IJH97.A10424
    • JM Li Y Shen DP Wu, et al. 2005 Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients Int J Hematol 82 1 48 54 16105759 10.1532/IJH97.A10424 1:CAS:528:DC%2BD2MXps1KiurY%3D (Pubitemid 41512199)
    • (2005) International Journal of Hematology , vol.82 , Issue.1 , pp. 48-54
    • Li, J.M.1    Shen, Y.2    Wu, D.P.3    Liang, H.4    Jin, J.5    Chen, F.Y.6    Song, Y.P.7    Wang, J.M.8    Qiu, X.F.9    Hou, M.10    Qiu, Z.C.11    Shen, Z.X.12
  • 16
    • 79956294708 scopus 로고    scopus 로고
    • Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
    • 21483003 10.1200/JCO.2010.30.9245
    • M Lübbert S Suciu L Baila, et al. 2011 Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group J Clin Oncol 29 15 1987 1996 21483003 10.1200/JCO.2010.30.9245
    • (2011) J Clin Oncol , vol.29 , Issue.15 , pp. 1987-1996
    • Lübbert, M.1    Suciu, S.2    Baila, L.3
  • 17
    • 16344369386 scopus 로고    scopus 로고
    • Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells
    • 15788130 1:CAS:528:DC%2BD2MXjslCqsLg%3D
    • WY Mai MF Lin 2005 Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells Chin Med J 118 6 487 492 15788130 1:CAS:528:DC%2BD2MXjslCqsLg%3D
    • (2005) Chin Med J , vol.118 , Issue.6 , pp. 487-492
    • Mai, W.Y.1    Lin, M.F.2
  • 18
    • 75049084540 scopus 로고    scopus 로고
    • Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group
    • 20047095 10.1007/s12185-009-0473-4
    • Y Morita A Kanamaru Y Miyazaki, et al. 2010 Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group Int J Hematol 91 1 97 103 20047095 10.1007/s12185-009-0473-4
    • (2010) Int J Hematol , vol.91 , Issue.1 , pp. 97-103
    • Morita, Y.1    Kanamaru, A.2    Miyazaki, Y.3
  • 19
    • 0036739696 scopus 로고    scopus 로고
    • Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia: Two parallel studies adjusted for various prognostic factors
    • 12200672 10.1038/sj.leu.2402591 1:CAS:528:DC%2BD38XmsV2lsbg%3D
    • M Oosterveld P Muus S Suciu, et al. 2002 Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia: two parallel studies adjusted for various prognostic factors Leukemia 16 9 1615 1621 12200672 10.1038/sj.leu.2402591 1:CAS:528:DC%2BD38XmsV2lsbg%3D
    • (2002) Leukemia , vol.16 , Issue.9 , pp. 1615-1621
    • Oosterveld, M.1    Muus, P.2    Suciu, S.3
  • 20
    • 17744419792 scopus 로고    scopus 로고
    • Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation
    • 10846828 1:CAS:528:DC%2BD3cXovVShurg%3D
    • K Saito Y Nakamura M Aoyagi, et al. 2000 Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation Int J Hematol 71 3 238 244 10846828 1:CAS:528:DC%2BD3cXovVShurg%3D
    • (2000) Int J Hematol , vol.71 , Issue.3 , pp. 238-244
    • Saito, K.1    Nakamura, Y.2    Aoyagi, M.3
  • 22
    • 68949145132 scopus 로고    scopus 로고
    • Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial
    • 19528372 10.1200/JCO.2008.19.6550 1:CAS:528:DC%2BD1MXhtFaitrrI
    • DP Steensma MR Baer JL Slack, et al. 2009 Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial J Clin Oncol 27 23 3842 3848 19528372 10.1200/JCO.2008.19.6550 1:CAS:528: DC%2BD1MXhtFaitrrI
    • (2009) J Clin Oncol , vol.27 , Issue.23 , pp. 3842-3848
    • Steensma, D.P.1    Baer, M.R.2    Slack, J.L.3
  • 23
    • 77950076360 scopus 로고    scopus 로고
    • Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia
    • 19744710 10.1016/j.leukres.2009.08.010 1:CAS:528:DC%2BC3cXjvFyltLo%3D
    • H Suzushima N Wada H Yamasaki, et al. 2010 Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia Leuk Res 34 5 610 614 19744710 10.1016/j.leukres.2009.08.010 1:CAS:528:DC%2BC3cXjvFyltLo%3D
    • (2010) Leuk Res , vol.34 , Issue.5 , pp. 610-614
    • Suzushima, H.1    Wada, N.2    Yamasaki, H.3
  • 24
    • 69249219029 scopus 로고    scopus 로고
    • A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: A single center experience from China
    • 19642997 10.1186/1756-8722-2-32 1:CAS:528:DC%2BD1MXhtFCgu7vM
    • J Wang S Lü J Yang, et al. 2009 A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China J Hematol Oncol 2 32 19642997 10.1186/1756-8722-2-32 1:CAS:528:DC%2BD1MXhtFCgu7vM
    • (2009) J Hematol Oncol , vol.2 , pp. 32
    • Wang, J.1    Lü, S.2    Yang, J.3
  • 25
    • 0028942481 scopus 로고
    • Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: A pilot study
    • 7531259 1:STN:280:DyaK2M7kslClug%3D%3D
    • K Yamada S Furusawa K Saito, et al. 1995 Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study Leukemia 9 1 10 14 7531259 1:STN:280:DyaK2M7kslClug%3D%3D
    • (1995) Leukemia , vol.9 , Issue.1 , pp. 10-14
    • Yamada, K.1    Furusawa, S.2    Saito, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.